Precision BioSciences Inc (DTIL) - Total Liabilities
Based on the latest financial reports, Precision BioSciences Inc (DTIL) has total liabilities worth $67.79 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Precision BioSciences Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Precision BioSciences Inc's total liabilities have evolved over time, based on quarterly financial data. See DTIL working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Precision BioSciences Inc Competitors by Total Liabilities
The table below lists competitors of Precision BioSciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ultra Chip
TWO:3141
|
Taiwan | NT$1.28 Billion |
|
Canyon Resources Ltd
AU:CAY
|
Australia | AU$6.50 Million |
|
Premia S.A.
AT:PREMIA
|
Greece | €457.50 Million |
|
Hwashin Precision Engineering Co. Ltd
KQ:126640
|
Korea | ₩108.61 Billion |
|
Omiris AG
F:HBD1
|
Germany | €1.83 Million |
|
Telecomunicações Brasileiras S.A. - TELEBRÁS
SA:TELB3
|
Brazil | R$2.66 Billion |
|
Agung Podomoro Land Tbk
JK:APLN
|
Indonesia | Rp12.08 Trillion |
|
BLE KEDROS REIC EO 1
F:N67
|
Germany | €18.20 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Precision BioSciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DTIL market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Precision BioSciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Precision BioSciences Inc (2016–2025)
The table below shows the annual total liabilities of Precision BioSciences Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $62.17 Million | -22.29% |
| 2024-12-31 | $80.00 Million | -43.23% |
| 2023-12-31 | $140.92 Million | -20.71% |
| 2022-12-31 | $177.74 Million | +47.71% |
| 2021-12-31 | $120.33 Million | +13.81% |
| 2020-12-31 | $105.73 Million | +9.09% |
| 2019-12-31 | $96.92 Million | -1.74% |
| 2018-12-31 | $98.64 Million | -0.41% |
| 2017-12-31 | $99.05 Million | -3.99% |
| 2016-12-31 | $103.16 Million | -- |
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalent… Read more